Trial Profile
A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs ASP-1948 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astellas Pharma Global Development
- 07 Mar 2024 Number of treatment arms has been changed from 6 to 13. 2) Primary endpoints has been amended.
- 26 Apr 2023 Status changed from active, no longer recruiting to completed.
- 19 May 2022 Planned End Date changed from 30 Apr 2024 to 30 Jun 2024.